The pathogenesis of adhesions following primary tendon repair is poorly understood, but is thought to involve dysregulation of matrix metalloproteinases (Mmps). We have previously demonstrated that Mmp9 gene expression is increased during the inflammatory phase following murine flexor digitorum (FDL) tendon repair in association with increased adhesions. To further investigate the role of Mmp9, the cellular, molecular, and biomechanical features of healing were examined in WT and Mmp9−/− mice using the FDL tendon repair model. Adhesions persisted in WT, but were reduced in Mmp9−/− mice by 21 days without any decrease in strength. Deletion of Mmp9 resulted in accelerated expression of neo-tendon associated genes, Gdf5 and Smad8, and delayed expression of collagen I and collagen III. Furthermore, WT bone marrow cells (GFP+) migrated specifically to the tendon repair site. Transplanting myeloablated Mmp9−/− mice with WT marrow cells resulted in greater adhesions than observed in Mmp9−/− mice and similar to those seen in WT mice. These studies show that Mmp9 is primarily derived from bone marrow cells that migrate to the repair site, and mediates adhesion formation in injured tendons. Mmp9 is a potential target to limit adhesion formation in tendon healing.
Citation: Loiselle AE, Frisch BJ, Wolenski M, Jacobson JA, Calvi LM, Schwarz EM, et al. (2012) Bone Marrow-Derived Matrix Metalloproteinase-9 Is Associated with Fibrous Adhesion Formation after Murine Flexor Tendon Injury. PLoS ONE 7(7): e40602. doi:10.1371/journal.pone.0040602
Editor: Elizabeth G. Laird, University of Liverpool, United Kingdom
Received: February 7, 2012; Accepted: June 11, 2012; Published: July 11, 2012
Copyright: © 2012 Loiselle et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was partially supported by National Institutes of Health grant number AR056696 from NIAMS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding received for this study.
Competing interests: The authors have declared that no competing interests exist.
While flexor tendon repair following traumatic transection restores the continuity of the tendon tissue, the healing process is frequently complicated by scarring and adhesion formation , . The scar tissue formed in association with the injury and repair process impedes the ability of low friction gliding of the tendon through the tendon synovial sheath. Clinical interventions such as controlled passive motion (CPM) ,  therapy protocols have reduced but not eliminated adhesion formation. The lack of motion of one of the fingers interferes substantially with the function of the entire hand. Although flexor tendon injuries are common and simple to surgically repair, the injury is associated with significant disability and physical impairment.
Tendon healing is a complex process that involves the coordinated interaction of numerous cell types. Following injury, an initial inflammatory reaction including hematoma formation occurs within 24 hours. Inflammatory cells such as neutrophils and macrophages migrate to the repair site, and engulf cellular debris , while tenocytes initiate synthesis of tendon extracellular matrix. The proliferative phase of healing is marked by the rapid deposition of an abundant but disorganized collagen matrix that is composed primarily of type III collagen. The newly synthesized collagen matrix re-establishes continuity of the tendon and provides some mechanical strength. During this phase of healing the tendon ends adjacent to the injury site undergo catabolism  and are replaced with granulation tissue. This expands the initial zone of injury and increases the total volume of tissue involved in the injury and repair process. While the exuberant injury response ensures healing and reconstitutes tendon strength, it increases scarring. The tendon becomes adherent to adjacent structures and the impaired tendon gliding ultimately decreases the overall finger arc of motion. The proliferative phase begins about four days after repair, and lasts for four weeks in human tendon healing . In this murine model, the proliferative phases occurs until about 14 days post-repair . Over time the repair tissue undergoes remodeling, synthesis of type I collagen is increased, and scar tissue is replaced with normal tendon. Thus, minimizing the formation of scar tissue while maximizing tendon strength is a goal of successful flexor tendon repair .
A potential strategy to decrease adhesions involves reduction of the initial zone of injury by limiting the catabolism of tendon tissues adjacent to the injury site. Type I Collagen comprises between 65–85% of the normal tendon , , , . Matrix Metalloproteinase-9 (Mmp9; Gelatinase B) is involved in the early neo-vascularization that occurs at sites of injury, and may be involved in degradation of the extracellular collagen matrix , . In human tendon tissue derived from patients with degenerative patellar tendinopathy, rotator cuff tendinitis, and Achilles tendon rupture, Mmp9 up-regulation is observed , , . Mmp9 is implicated in scar formation in the spinal cord  and the lung . In an experimental model of intrasynovial murine flexor tendon repair, we recently demonstrated elevated Mmp9 expression during the early-inflammatory period of tendon healing . This is the period of maximal tissue catabolism and extension of the zone of injury.
Mmp9 has been implicated in scarring following myocardial injury, central nervous system injury, lung injury, liver injury, and in kidney disease , , , , , , , . Furthermore, Mmp9 gene deletion results in reduced interstitial fibrotic lesions in mice with obstructive nephropathy, inhibits allergen induced lung fibrosis, and attenuates fibrosis in the liver following injury , , . A polymorphism that results in decreased expression of the Mmp9 gene is associated with decreased scar formation and blindness in patients with trachoma eye infection . Collectively, these observations suggest that Mmp9 is directly involved in scar formation during adult tissue repair.
The source of Mmp9 in injury and repair processes can either be local stromal cells, bone marrow cells, or systemically derived macrophages or mesenchymal precursors recruited to the injury site , , , . Inflammatory cytokines induced by injury or other conditions stimulate Mmp9 expression in tissue fibroblasts . For example, neural stem cells in a hypoxic environment have a five-fold up-regulation of Mmp9 . Astrocytes, kidney mesangial cells, and cardiac, synovial and dermal fibroblasts also have been shown to express Mmp9 , , , , , . Macrophages recruited to the injured tissues have been shown to be a major source of Mmp9 expression in central nervous system injury, liver fibrosis, and pulmonary disease , , . Bone marrow-derived hematopoietic cells expressing Mmp9 are recruited to skin cancers where they modulate tumor invasiveness in a mouse model .
This study defines the role of Mmp9 during tendon healing and in the process of adhesion formation using a murine intrasynovial flexor digitorum longus tendon injury and repair model , . Tendon injuries heal in Mmp9−/− mice with decreased adhesions, more robust tissue remodeling and with accelerated expression of molecular markers of tendon differentiation. Transplantation of bone marrow from Mmp9−/− donor mice into irradiated WT (wild type) recipients and vice versa, demonstrates that Mmp9 expression during tendon repair is derived from cells that originate in the bone marrow and migrate to the injury site. This work identifies a novel molecular and cellular target for therapeutic intervention to preempt formation of fibrous adhesions after flexor tendon injury.
Loss of Mmp9 Alters Gene Expression during Flexor Tendon Healing
An intrasynovial FDL tendon repair model ,  was used in Mmp9−/− and WT mice to examine the role of Mmp9 in tendon healing. Prior experiments in this model have shown peaks of Mmp9 and Col3 expression during the early-inflammatory phase of healing (seven-10 days), followed by a shift to Col1 expression (14 days), and induction of Mmp2 at the initiation of the remodeling phase of tendon healing when adhesion formation is highest (21 days). The expression of the tendon-associated transcription factor Smad8 ,  and tendon associated growth factor Gdf5 are both markedly up-regulated between 28 and 35 days. This pattern of gene expression is associated with a reduction in the gliding coefficient (a biomechanical measure of adhesions), and a transition to tissue morphology that more closely resembles normal tendon tissue rather than scar tissue .
The expression of genes associated with the inflammatory, proliferative and remodeling phases of healing in FDL injured tendons of WT and Mmp9−/− mice were analyzed by real-time RT-PCR and normalized to their expression level in day three repairs in WT mice (Figure 1). Peak expression of Cox-2, an important mediator of inflammation, occurred at three days post-repair in WT and Mmp9−/− tendons, however, expression was not significantly different between groups at this time (p>0.05). Cox-2 was not differentially expressed between WT and Mmp9−/− at any time during healing, with slight, but in-significant decreases after day three (Figure S1). Mmp9 was not expressed in reparative tissues in Mmp9−/− mice, but its expression in WT mice was similar to that observed in prior studies , with peak expression at seven days and a return to control levels by 14 days (Figure 1A). Type III Collagen (Col3), which is associated with granulation tissue, was increased at seven days post-repair in WT mice (3.2-fold), and had peak expression at 10 days post-repair (10.8-fold increase). Col3 expression remained significantly elevated through 14 days (5.5-fold increase), after which time expression returned to baseline levels in WT mice (Figure 1B). In WT mice, peak expression of Col1 was observed on day 14 post-repair (4.4-fold increase) and persisted through day 28 (2-fold increase; Figure 1C). In contrast, both Col3 and Col1 expressions were delayed in Mmp9−/− mice. Col3 expression was not significantly increased in Mmp9−/− mice until day 21 (8.3-fold increase), but remained significantly elevated through day 28 (7.7-fold increase). The pattern of Col1 expression in Mmp9−/− mice was similar to that observed with Col3. Peak expression of Col1 occurred on day 21 (6.2-fold increase), and remained elevated through day 28 (2.7-fold increase; Figure 1B&C).
−/− mice. Gene expression of (A) Mmp9 (B) Col3a1, (C) Col1a1, (D) Mmp2, (E) Gdf5, and (F) Smad8 in FDL tendon repair tissue over time up to 28 days post-op. Total RNA was extracted and pooled from five tendon repairs per time-point and processed for real-time RT-PCR. Gene expression was standardized with the internal β-actin control and then normalized by the level of expression in day three WT FDL tendon repairs. Data presented as the mean fold induction (over WT day three repairs) ± SEM. * p<0.05 vs. WT day three tendon repair. White bars represent WT mice. Black bars represent Mmp9−/− mice.
Mmp2 (Gelatinase A) expression is associated with the tissue remodeling phase of tendon healing when adhesions decrease . Mmp2 was expressed earlier and at increased levels in tendon repairs in Mmp9−/− mice compared to WT mice (Figure 1D). Mmp2 expression was increased beginning at day 14 post-repair (21-fold increase; Figure 1D) in Mmp9−/− mice, and peak expression occurred on day 21 (56-fold increase). At day 28 Mmp2 expression remained elevated (4.7-fold increase). In contrast, elevation of Mmp2 expression was not observed until day 21 in WT mice (12-fold increase), although this also represented the point of maximal expression in these mice. At day 28, expression of Mmp2 decreased relative to day 21, but remained elevated (5.1-fold increase) compared to day three WT controls.
The earlier and more robust expression of Mmp2 in the tendon repairs of Mmp9−/− mice suggests more vigorous and rapid tendon regeneration and remodeling. To further examine this possibility, the expression of genes associated with neo-tendon formation, Gdf5 and Smad8 were examined in tendon repair tissues in Mmp9−/− and WT mice , , . In healing tendons in WT mice, Gdf5 and Smad8 expression became elevated only late in the repair process (day 28) and following the peak expression of Mmp2. Gdf5 was increased 2.5-fold and Smad8 was increased 106-fold at 28 days following injury in WT mice. In contrast, the expression of these neo-tendon related genes was markedly accelerated in Mmp9−/− mice. Gdf5 was elevated by seven days post-repair (4.4-fold), and elevated expression persisted through day 14 (29.3 fold increase; Figure 1E). Smad8 was also induced by seven days following tendon repair in Mmp9−/− mice (10.5-fold increase; Figure 1F), and remained elevated through day 28, when a 119-fold increase was observed.
Mmp9−/− Tendons have a Reduced Zone of Injury
Histology was used to assess changes in the structure and morphology of healing FDL tendons. There were no observable differences in the structure of sham control tendons between WT and Mmp9−/− mice (Figure 2 A&B).
−/− mice. Representative histological sections of sham control WT (A) and Mmp9−/− (B) FDL Tendons. Repaired WT and Mmp9−/− FDL Tendons at days 7 (C, D), 10 (E, F), 14 (G, H) 21 (I, K) and 28 (K, L). Sections were stained with Alcian Blue/Hematoxylin and Orange G. Of note is the fibroblastic granulation tissue that fills in the repair site between tendon ends (marked as T) and is progressively remodeled (green box) with collagen becoming oriented in a parallel fashion with the long axis of the tendon. Black bar represents width of WT tendon; yellow bar represents width of Mmp9−/− tendon at Day 21. Scale bars represent 200 microns. 5X magnification.
In WT mice at seven days post repair, a reactive, cellular granulation tissue developed adjacent to the tendon repair site and at the repair site (Figure 2C). At day 10 post-repair, granulation tissue was more cellular and the native collagen tissue adjacent to the repair site underwent catabolism and invasion by the reactive granulation tissue (Figure 2E). At 14 days the ends of the tendon were bridged at the repair site by granulation tissue and an external callus of thickened granulation tissue encased the repair site and adjacent tendon tissue (Figure 2G). At day 21, the granulation tissue reached maximal thickness. The tissue was composed of disorganized collagen fascicles, which replaced the tendon ends adjacent to the repair (Figure 2I). At day 28 remodeling of the tendon occurred with thinning of the granulation tissues that encased the tendon. At this time point extensive remodeling and replacement of the original tendon tissue was observed, with more organized tissue that was oriented parallel to the long axis of the tendon. The area of tendon replacement by the healing scar tissues comprised the entire zone of injury and is show with the green box (Figure 2K).
The tendon repair process in Mmp9−/− mice had similarities and some unique features compared to WT repairs. While WT and Mmp9−/− tendons healed with increased granulation tissue at the repair site by day seven (Figure 2C&D), the width of the granulation tissue was reduced at subsequent time points in Mmp9−/− repairs (Days 10, 14, 21, and 28; Figures 2F, 2H, 2J, and 2L). The difference in the width of the reparative tissue is apparent in the photomicrographs following repair in the WT and Mmp9−/− mice. The black bar (Figure 2I and 2J) shows the width of the granulation tissue in WT mice compared to the width of the granulation tissue in the Mmp9−/− mice (yellow bar; Figure 2J). Another distinguishing feature is that the degree of catabolism of native tendon tissue adjacent to the repair site is reduced. This results in a reduction of the extent of the zone of injury. This is readily apparent on photomicrographs of WT and Mmp9−/− repair tissues at day 28. The green boxes show the extent of the zone of injury and area of native tendon replacement and remodeling in WT mice (Figure 2K) and Mmp9−/− mice (Figure 2L). Altogether, the molecular and histological data show that Mmp9−/− mice undergo tendon healing with less catabolism and extension of the zone of injury and have a concomitant acceleration of the reduction and remodeling of granulation tissues.
Adhesions are Remodeled Earlier in Mmp9−/− Flexor Tendons
The gliding coefficient is derived from a biomechanical measurement of metatarsal-phalangeal (MTP) joint range of motion following a series of applied loads to the tendon , . An elevated gliding coefficient is associated with a higher force required for a given degree of flexion, and therefore is an index of scar and adhesion formation , . The baseline WT gliding coefficient was not statistically different than the controls from Mmp9−/− mice. The gliding coefficient was increased at day 10 and day 14 in the repairs from both WT and Mmp9−/− mice. However, there was no significant difference in the gliding coefficients at these time points, and in both WT and Mmp9−/− mice maximal adhesions occurred at 14 days (WT, 4.1-fold; Mmp9−/− mice, 5.8-fold; Figure 3). A significant difference was observed beginning at 21 days following repair. In Mmp9−/− mice the gliding coefficient had returned to baseline levels, consistent with tendon remodeling. In contrast, the gliding coefficient remained elevated in the repairs of the WT mice at 21 days (2-fold). Similar differences were observed at 28 days. Thus the biomechanical measure of the tissue adhesions further confirms that Mmp9−/− mice undergo tendon repair with reduced scar formation.
−/− tendon repairs. Gliding coefficient of WT and Mmp9−/− mouse FDL tendon repairs over time up to 28 days post-repair. Repair data is compared to sham control tendons (mean ± SEM). (*) Indicates significant difference versus respective control, while (#) indicates significant difference versus Day 14 Mmp9−/− repair.
Strength and Stiffness are Maintained in the Repairs of Mmp9−/− Mice
Biomechanical measurement of the maximum tensile load at failure of repaired and control tendons were determined in both the WT and the Mmp9−/− mice (Table 1). Control tendons in the WT and Mmp9−/− mice had a similar load at failure. Following repair, the maximum load at failure was markedly decreased after 14 days of healing in both WT mice (8.8% of control) and Mmp9−/− mice (16.4% of control) (Table 1). The maximal load at failure progressively increased as the repair progressed. However, by 28 days, repaired tendons in WT mice had reached only 25% of the maximum load at failure of un-operated WT tendon, while repaired tendons in Mmp9−/− mice had regained only 31% of the maximum load at failure of un-operated Mmp9−/− tendon.
The stiffness (the slope of the linear region of the force displacement curve) of the control and repaired tendons in WT mice and Mmp9−/− mice were also measured (Table 2). Similar stiffness was observed in the control (un-operated) tendons from WT mice and Mmp9−/− mice (Table 2). As with measurements of strength, the stiffness of the repaired tendons also increased with the time of healing. The stiffness of the tendon repairs of the WT and Mmp9−/− mice were similar at each time point. At 14 days, Mmp9−/− repairs were 36% stiffer than WT, although this difference was not significant (p = 0.13). At 28 days repaired tendons in the WT mice and Mmp9−/− mice regained 44.9% and 45.9% of their stiffness, respectively (Table 2).
Bone Marrow Derived Cells Migrate to the Flexor Tendon Repair Site
To determine the ability of bone marrow-derived cells to migrate to the flexor tendon repair site, bone marrow mononuclear cells from C57B6/J GFP+ transgenic mice were transplanted into WT C57B6/J mice following conditioning whole body irradiation. After allowing the transplanted cells to engraft, the mice underwent flexor tendon transection and repair.
The presence of bone marrow-derived cells at the repair site was determined by examining histological sections of healing tendon with fluorescent imaging for the expression of GFP. GFP+ cells were not observed in un-injured contralateral sham control tendons (Figure 4A). However, GFP+ cells were observed in the healing tendon tissues where they localized to the reparative granulation tissues. GFP+ cells were present three days after repair (Figure 4B) and increased numbers were observed by seven days (Figure 4C). GFP+ bone marrow-derived cells remained abundant at 14 days following repair and they were localized to the healing granulation tissue (Figure 4D). By day 21, GFP+ bone marrow derived cells were diffusely located throughout the granulation tissue and in areas of remodeled tendon tissue (Figure 4E). At 28 days post-repair the remaining GFP+ cells were present in the area of tendon remodeling (Figure 4F).
Representative sections of repaired flexor tendons from C57Bl6/J mice that were myeloablated, and reconstituted with bone marrow from GFP transgenic mice. Tendons were repaired after bone marrow cells had engrafted, and tissues were harvested between three and 28 days post-repair. Sections were counterstained with the nuclear dye DAPI (blue) and bone marrow derived cells were identified based on the expression of GFP. Contralateral sham controls (A) did not have any GFP expressing cells indicating a lack of bone marrow cells in un-injured tendon, while bone marrow derived cells are present at the FDL repair site at (B) three, (C) seven, (D) 14, (E) 21, and (F) 28 days post-repair. Tendon tissue is outlined in orange and marked as ‘T’. All images are 10x magnification. Scale bars represent 200 microns.
Mmp9 is Expressed by Bone Marrow-derived Cells during Flexor Tendon Healing
In order to determine if bone marrow-derived cells migrating to the injury site provide local Mmp9 expression in tendon repair, reciprocal bone marrow transplants were conducted in which WT mice received Mmp9−/− bone marrow transplantation, and Mmp9−/− mice received WT bone marrow transplantation.
The expression of Mmp9 was examined by real time RT-PCR in tissue extracted from the healing tendons of WT mice; WT mice following transplantation with Mmp9−/− bone marrow cells; Mmp9−/− mice; and Mmp9−/− mice following transplantation with WT bone marrow cells (Figure 5A). Since we demonstrated earlier (Figure1A) that during tendon repair Mmp9 expression peaks at day seven post injury, tissues from the repaired tendons were harvested at three and seven days post-repair and analyzed by real-time RT-PCR for expression of Mmp9. WT mice had Mmp9 expression measured at three days following repair and this level of expression was used as a baseline level of normalized expression (1.0±0.54). Mmp9 expression increased 4.1-fold at day seven in the WT mice. In contrast, WT mice with transplantation of Mmp9−/− bone marrow cells did not have measurable levels of expression of Mmp9 at day three and had minimal expression at day seven following repair (0.059±0.03; p<0.05, compared to the expression level in day three post-repair WT tendons). As expected, repairs from Mmp9−/− mice lacked Mmp9 gene expression. However, in Mmp9−/− mice transplanted with bone marrow cells from WT mice, no detectable Mmp9 expression was observed three days following repair, whereas a 2.3-fold increase (p<0.05; compared to WT day three expression) was observed at seven days after tendon repair (Figure 5). Collectively, these data show that Mmp9 expression during tendon repair is dependent upon migration of bone marrow-derived cells to the injury site.
−/− bone marrow. Real-time RT-PCR for Mmp9 expression in WT, Mmp9−/− (KO), WT mice transplanted with bone marrow from an Mmp9−/− donor (WT [KO Bone Marrow]), Mmp9−/− mice transplanted with bone marrow from a WT donor (KO [WT Bone Marrow]) in repaired flexor tendons at three and seven days post-repair. Expression is normalized to β-actin, and compared day three expression in WT mice. Data are presented as mean ± SEM. (*) Indicates a significant difference compared to WT day three expression.
To determine the influence of host cells on bone marrow transplantation, the level of Mmp9 expression in bone marrow from WT mice receiving Mmp9−/− bone marrow, and Mmp9−/− mice receiving WT bone marrow were analyzed. Mmp9−/− mice with WT bone marrow had a significant 18.5-fold induction (p = 0.001) of Mmp9 expression relative to WT mice with Mmp9−/− bone marrow at seven days post-repair (Figure S2). There was a 2.84-fold increase in Mmp9 expression in bone marrow from WT mice with Mmp9−/− bone marrow, relative to Mmp9 expression in tendon tissue in these mice, suggesting the presence of some host WT cells in the bone marrow of WT mice with Mmp9−/− bone marrow.
Mmp9 Deficient Bone Marrow Cells are Associated with Decreased Tendon Adhesions
Quantification of adhesions and biomechanical testing was done to determine the functional consequences of both bone marrow cell-specific deletion of Mmp9, and expression of Mmp9 solely in bone marrow cells during flexor tendon healing.
To further define the role of bone marrow cell derived Mmp9 in adhesion formation, MTP joint flexion tests were performed in Mmp9−/− mice and in Mmp9−/− mice following transplantation with WT bone marrow cells (Figure 6A). As previously shown, Mmp9−/− mice had a reduced gliding coefficient during tendon healing, compared to WT controls. At 14 days following repair, the gliding coefficient was increased 8.3-fold, but was reduced to basal levels at day 21 and 28. In contrast, the transplantation of WT bone marrow cells into Mmp9−/− mice resulted in an increased in gliding coefficient that mimicked the pattern of adhesions observed in WT mice undergoing tendon repair. Mmp9−/− mice with WT bone marrow transplantation had a maximal gliding coefficient at 21 days (9-fold), but had sustained elevation of the gliding coefficient at 28 days (6-fold). The gliding coefficient was significantly elevated in the tendon repairs of the Mmp9−/− mice with WT bone marrow transplantation compared to the tendon repairs of the Mmp9−/− mice at 21 and 28 days. Therefore, rescue of Mmp9 expression in bone marrow-derived cells is sufficient to reestablish tendon scarring after injury in Mmp9-deficient mice.
−/− mice results in prolonged presence of adhesions during tendon healing. Gliding coefficient based on range of applied load of FDL tendon repairs from [A] Mmp9−/− mice, and Mmp9−/− mice with WT bone marrow; [B] WT, and WT with Mmp9−/− bone marrow between 14 and 28 days post-repair. (*) Indicates p<0.05 compared to respective control, # indicates p<0.05 compared to Mmp9−/− repair at the same time-point. Data are presented as mean ± SEM.
Adhesions were also measured in WT mice and in WT mice following transplantation with Mmp9−/− bone marrow cells (Figure 6B). As previously shown, WT mice had a maximal increase in the gliding coefficient at 14 days after repair (approximately 4-fold) followed by a decrease at 21 (2.1-fold) and 28 (2.3-fold) days following repair. WT mice with transplanted Mmp9−/− bone marrow cells similarly had maximal gliding coefficients at 14 days followed by a decrease at 21 and 28 days after repair. The gliding coefficients in the WT mice and in WT mice with Mmp9−/− bone marrow cell transplants were not significantly different, suggesting that even very low levels of Mmp9 produced locally in the healing tissues might be produced by cells other than migrating marrow cells. This could include the low levels of Mmp9 produced by tenocytes, or alternatively, some other cell types. Another explanation is that other factors or non-marrow cell populations are also involved in the adhesion formation that occurs in this model. Finally, based upon low, but detectable expression of Mmp9 in the bone marrow of WT mice with Mmp9−/− bone marrow, there appear to be a small number residual WT bone marrow cells after conditioning radiation, which could provide sufficient Mmp9 to result in scarring.
As a control for any possible effects of whole body irradiation and bone marrow transplantation, tendon repairs were performed and the gliding coefficient measured in transplant control mice (WT bone marrow cells transplanted in WT mice; and Mmp9−/− bone marrow cells transplanted into Mmp9−/− mice). There was no significant difference between the gliding coefficient in transplant controls compared to WT and Mmp9−/− mice respectively at any time post-repair (data not shown).
Bone Marrow-specific Loss of Mmp9 does Not Decrease the Maximum Load at Failure
Following adhesion testing, the tensile properties of repaired tendons were measured. There was no difference in the basal maximum load at failure of tendons from mice that received bone marrow transplants or un-transplanted WT mice and Mmp9−/− mice (Table 3). After repair, the maximum load at failure was significantly lower than controls in all groups, but the maximum load at failure of repairs from Mmp9−/− mice with WT bone marrow cells was not significantly different than those from WT mice with Mmp9−/− bone marrow at any time. On day 28, tendons from WT mice with Mmp9−/− bone marrow regained 22% of the maximum load at failure of control tendons, while Mmp9−/− mice with WT bone marrow transplantation regained 19% of load to failure in control tendons (Table 3).
The stiffness of repaired tendons from these groups of mice was also analyzed. There was no significant difference between control specimens for any of the groups. At 14 days post-repair, the stiffness of all groups was significantly decreased compared to all controls, and stiffness of the repaired tendons remained significantly decreased compared to controls in all groups through 28 days post-repair. At day 28 post-repair, the stiffness of tendons from Mmp9−/− mice with WT bone marrow transplantation was significantly decreased (p<0.05) compared to WT mice with Mmp9−/− bone marrow transplantation (Table 4).
We show that complete loss of Mmp9 during flexor tendon healing results in earlier remodeling of adhesions compared to WT mice, without loss of repaired tendon strength. Accelerated, and increased expression of Mmp2, Gdf5 and Smad8 suggest the remodeling phase of flexor tendon healing occurs earlier in Mmp9−/− mice, resulting in the subsequent decrease in the gliding coefficient. Additionally, the contribution of bone marrow-derived cells to the flexor tendon healing process was demonstrated by presence of GFP-expressing cells in WT mice following bone marrow transplant of GFP+ cells. The functional role of Mmp9 expression in bone marrow-derived cells was demonstrated by the increased adhesions that occurred in myeloablated Mmp9−/− mice transplanted with WT bone marrow cells. The gliding coefficient was similar to that observed in tendon repairs of WT mice. Notably, the strength and stiffness of repairs in Mmp9−/− mice were similar to those observed in WT mice. Thus, lack of Mmp9 reduces tendon adhesions but does not result in a weaker repair tissue.
Based on the causal association between inflammation and adhesion formation , , previous work has altered the healing course with anti-inflammatory treatment , . These studies have demonstrated that an attenuated inflammatory response can decrease adhesions, however, decreased adhesions are often accompanied by a decrease in the strength of the repair during the early phases of healing, rendering these tendons unsuitable for aggressive physical therapy, and prone to re-rupture , . Virchenko et al have shown that an early decrease in force at failure resulted from Cox-2 inhibition , suggesting that altering the normal cascade of inflammatory events leads to a decrease in the force at failure. Furthermore, a greater proportion of untreated specimens had a higher histology score, corresponding a greater amount of mature tissue, suggesting a larger zone of injury in mice treated with a Cox-2 inhibitor. In contrast, our work shows that deletion of Mmp9 results in reduced catabolism of native tendon and a development of a smaller zone of injury compared to WT repairs. However, there is no reduction in the maximum load at failure compared to tendon repairs in WT mice. This is an important distinction because a decrease in the maximum load at failure increases the likelihood of rupture. Our data indicate that targeted inhibition of early Mmp9 expression may improve flexor tendon healing.
The robust remodeling of adhesions and the decreased gliding coefficient by day 21 in Mmp9−/− mice suggests an accelerated remodeling phase. Prior work in our laboratory has shown that tendon remodeling is associated with elevated expression of Mmp2 . Elevated expression of Mmp2 occurs earlier in Mmp9−/− mice (14 days) compared to WT mice (21 days). Mmp2 expression is increased immediately before a significant decrease in the gliding coefficient, suggesting an important role for Mmp2 in scar remodeling. The reduced area of initial catabolism of tendon adjacent to the repair site in tendons from Mmp9−/− mice suggests that while degradation of some native tissue is beneficial, too much catabolism results in a more abundant response with a prolonged period of increased adhesions. While lack of Mmp9 results in a change in the kinetics of tendon remodeling, the overall mechanical strength of the tendon repair, a key component of tissue regeneration, is not reduced in the Mmp9−/− mice. The return of tendon strength requires a balance between degradation, collagen formation, and tissue remodeling. Alteration in the expression of Mmp9 changes the anabolic phase of healing, suggesting that Mmp9 expression is a key regulator of subsequent tissue responses.
We show that bone marrow cells migrate to the flexor tendon repair site consistent with a prior report showing migration to the patella tendon repair site . By day seven post-repair there is a large influx of cells that declines, but persists through day 28. The important role of inflammatory mediators or chemotactic signaling in this “homing” process is demonstrated by the complete absence of GFP+ cells in contralateral control tendons, indicating that BMSCs migrate specifically to the site of injury. Our findings differ somewhat from other models of bone marrow cell migration to the tendon repair site. In a murine partial patella tendon defect model there is a massive influx of GFP+ cells to the repair site within 24 hours , while we found very few bone marrow cells at three days post-repair. The rate of healing and the disruption in vascularization in a partial defect model may be different than that of a complete transection. The presence of intact tendon at the repair site may increase the early intrinsic phase of healing, or increase the release of chemotactic signals from the tendon tissue that recruits bone marrow cells to the repair site. Additionally, the synovial sheath surrounding the flexor tendon may be an additional barrier that bone marrow cells must cross before arriving at the intrasynovial repair site.
Expression of Mmp9 specifically in cells derived from the bone marrow was achieved by bone marrow transplantation, while the functional consequences of bone marrow-specific Mmp9 deletion were also shown. Loss of Mmp9 in the bone marrow during flexor tendon healing resulted in earlier remodeling of adhesions, compared to those mice that express normal levels of Mmp9 in the bone marrow, as well as in mice with bone marrow cell-specific Mmp9 expression. Resolution of fibrous adhesions after flexor tendon injury did not occur to the same degree in mice with bone marrow cell-specific loss of Mmp9 compared to healing in Mmp9−/− mice. Based on the low-level expression of Mmp9 transcripts in tendons from WT mice with Mmp9−/− bone marrow, it appears that marrow cells are a major source of Mmp9 during flexor tendon healing. It appears that some WT host cells persisted in the bone marrow and provided a slight contribution of Mmp9 during flexor tendon healing. This would explain why there was not complete remodeling of adhesions to the extent of complete loss of Mmp9, and also why there was low, but detectable expression of Mmp9 in tendons from WT mice with Mmp9−/− bone marrow by real-time PCR.
Bone marrow-specific loss of Mmp9 leads to earlier remodeling of adhesions, without a decrease in the strength of the repair. This study presents a novel mechanism of improved flexor tendon healing, by inhibition of Mmp9, which in the setting of tendon repair seems to be primarily produced by bone marrow-derived cells. Small molecule Mmp9 inhibitors are currently in clinical trials for Multiple Sclerosis, Chronic Obstructive Pulmonary Disease and Prostate Cancer , , and may aid the pursuit of Mmp9 inhibition during tendon healing. This work demonstrates that it is possible to regain gliding function of the flexor tendon sooner, without compromising the strength of the repair. One limitation of this study is that we have not directly assessed the in vivo gelatinolytic activity of Mmp9 during flexor tendon healing. Identification of this activity would identify a novel target to improve flexor tendon healing.
All animal procedures were approved by the University Committee on Animal Research at the University of Rochester.
Mouse Strain Information
All mice were acquired from Jackson Laboratories (Bar Harbor, ME). Six to eight week old female Mmp9−/− (FVB.Cg-Mmp9tm1Tvu/J)  and WT (FVB/NJ) mice were used for tendon repair studies and bone marrow transplants. GFP transgenic (C57BL/6-Tg(UBC-GFP)30Scha/J) and C57BL/6 mice were used for initial bone marrow transplant studies.
Murine Flexor Tendon Injury and Repair
Complete transection and repair of murine flexor tendons was conducted as previously described  Six to eight week old female mice (Jackson Laboratories, Bar Harbor, ME) were anesthetized by intraperitoneal injection of 4 mg/kg xylazine and 60 mg/kg ketamine. The distal flexor digitorum longus (FDL) tendon was exposed and two horizontal 8-0 nylon sutures in a modified Kessler pattern were placed in the intact tendon. The tendon was then transected between the sutures and repaired by approximating the transected ends using the suture. The tendon was also transected proximally along the tibia at the myotendinous junction to protect the repair. The skin was closed with running 4-0 nylon sutures. The mice were returned to their cages and allowed free active motion and weight bearing following recovery from anesthesia. Sham surgeries were performed on control groups. Identical anesthesia and exposure were performed. When the distal FDL tendon was isolated, two horizontal 8-0 sutures in a modified Kessler pattern were sutured through the tendon. This suture was then removed without transecting the tendon. However the proximal FDL tendon was released at the myotendinous junction as in the repair group. The skin was closed with running 4-0 nylon sutures.
RNA Extraction and Real-Time RT-PCR
Tendons were harvested and RNA was extracted as previously described . Briefly, five repaired tendons per time-point per experimental group were harvested and RNA was extracted using TRIzol (Invitrogen). cDNA was reverse transcribed using 1ug of RNA and the iScript cDNA synthesis kit (BioRad). Real-Time PCR was done using Absolute qPCR SYBR (ABgene) and gene specific primers (Table 5). Gene expression was normalized to β-actin, and expression on day three in WT tendons due the relative metabolic inactivity of un-injured tendons.
Histological Analysis of Healing
Whole hind limbs containing repaired tendons were harvested between seven and 28 days post-repair as previously described . The intact foot and tibia were harvested by disarticulating the hind limb at the knee. Briefly, the hind limbs were fixed in 10% formalin with the tibia at 90° relative to the foot, and then decalcified in 10% EDTA at 4°C for 28 days. The decalcified tissues were dehydrated and embedded in paraffin to preserve the anatomical relationship between the repaired tendon and surrounding tissues. Serial three-micron sagittal sections through the FDL tendon plane were then cut and stained with Alcian Blue/Hematoxylin and Orange G. Four specimens per group per time-point were used, with approximately five sections per specimen analyzed.
Adhesion and Biomechanical Testing
Adhesion and biomechanical testing was completed as previously described , . The hind limb was disarticulated at the knee, and the FDL tendon was released from the surrounding tissue proximal to the tarsal tunnel. The FDL tendon was secured between two pieces of tape using superglue. The limb was fixed in a custom apparatus, and a digital image was taken of the MTP joint in a neutral unloaded position with the digits extended. Loads were incrementally applied to the flexor tendon and the MTP joint range of motion relative to the unloaded position was measured from a digital image. MTP joint flexion angles were measured using ImageJ software (http://rsb.info.nih.gov/ij/), and plotted versus the applied loads. The gliding coefficient was determined by non-linear regression as a measure of resistance to MTP flexion to due impaired gliding.
Immediately following adhesion testing, the proximal aspect of the FDL tendon was released from the tarsal tunnel, the calcaneus and tibia were removed and the proximal end of the FDL was gripped in the Instron device as previously described , . The distal bones of the foot were also secured in the Instron device (Instron 8841 DynaMight™ axial servohydraulic testing system, Instron Corporation, Norwood, MA). The tendon was tested in tension in displacement control at a rate of 30 mm/minute until failure. Force-displacement data were automatically logged and plotted and the maximum tensile force and stiffness were determined. N = 7–10 animals/group/time-point.
Biomechanical and Real-Time RT-PCR data were analyzed using a two-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparisons with a significance level of α = 0.05. p values are reported for significance compared to gene expression in WT day three samples; and biomechanical significance is reported compared to control tendons, except where otherwise stated.
Bone Marrow Transplantation
C57BL/6 mice (Jackson Labs) were myeloablated and bone marrow transplantation was performed as previously described . Briefly, an initial 5Gy whole body dose was given 24 hours prior to transplantation, and a second 5Gy dose was given two hours prior to transplantation. Whole bone marrow was aseptically isolated from mice expressing GFP in all tissues (C57BL/6-Tg (UBC-GFP) 30Scha/J, Jackson lab) and re-suspended in sterile PBS containing 2% FBS. Each mouse was given 5×105 GFP+ cells via tail vein injection. Animals were preemptively given Sulfatrim antibiotic (Activas, Baltimore, MD) in the drinking water beginning seven days prior to irradiation, and were maintained on antibiotics for two weeks post-transplantation. Mice were allowed to recover and cells engrafted for two weeks post-transplant. At this time, standard flexor tendon repair was performed, and tendons healed for between three and 28 days. Tendons were harvested from the tarsal tunnel to the bifurcation at the digits, and placed in 4% Paraformaldehyde for one hour. Tissues were washed twice in PBS for 15 minutes, and placed in 15% sucrose for 1 hour until tissue was saturated. Tissues were then placed in 30% sucrose for 16 hours, and embedded in OCT media. Eight-10uM sections were cut using a cryostat. Sections were post-fixed with 0.2% Glutaraldehyde for 10 minutes, washed twice with PBS, counterstained and cover slipped using Vectashield Mounting Medium with DAPI (Vector Laboratories, Burlingame, CA) GFP was localized using fluorescent microscopy. N = 3 bone marrow transplant recipients/time-point.
WT and Mmp9−/− bone marrow transplants were conducted in the same manner as described above, with tissues harvested for Real-time RT-PCR (N = 5/group/time-point), histology (N = 4/group/time-point; 5 sections/specimen), in situ hybridization, as well as biomechanical and adhesion testing (N = 7–10 group/time-point).
Cox-2 mRNA expression in WT (white bars) and Mmp9−/− (black bars) flexor tendons from three to 28 days post-repair. Data were normalized to β-actin, and WT day three expression. Data are presented as mean ± SEM.
Mmp9 mRNA expression in bone marrow from WT mice with Mmp9−/− bone marrow (white bar), and Mmp9−/− mice with WT bone marrow (black bar) at seven days post-repair. Data were normalized to β-actin, and expression in WT mice with Mmp9−/− bone marrow at seven days. (*) Indicates p<0.05, data are presented as mean ± SEM.
We would like to thank Ryan Tierney for technical assistance with histology, Dr. Tim Bushnell for assistance with flow cytometric analysis, and Dr. Matthew Hilton for helpful advice on this manuscript.
Conceived and designed the experiments: AEL LMC EMS HAA RJO. Performed the experiments: AEL BJF MW JAJ. Analyzed the data: AEL HAA RJO. Contributed reagents/materials/analysis tools: LMC HAA. Wrote the paper: AEL HAA RJO.
- 1. Beredjiklian PK (2003) Biologic aspects of flexor tendon laceration and repair. J Bone Joint Surg Am 85-A: 539–550.
- 2. Lin T (2004) Biomechanics of tendon inury and repair. Journal of Biomechanics 37: 865–877.
- 3. Gelberman RH, Botte MJ, Spiegelman JJ, Akeson WH (1986) The excursion and deformation of repaired flexor tendons treated with protected early motion. J Hand Surg [Am] 11: 106–110.
- 4. Gelberman RH, Woo SL, Lothringer K, Akeson WH, Amiel D (1982) Effects of early intermittent passive mobilization on healing canine flexor tendons. J Hand Surg [Am] 7: 170–175.
- 5. Sharma P, Maffulli N (2005) Basic biology of tendon injury and healing. Surgeon 3: 309–316.
- 6. Strickland JW (2000) Development of flexor tendon surgery: twenty-five years of progress. J Hand Surg [Am] 25: 214–235.
- 7. Loiselle AE, Bragdon GA, Jacobson JA, Hasslund S, Cortes ZE, et al. (2009) Remodeling of murine intrasynovial tendon adhesions following injury: MMP and neotendon gene expression. J Orthop Res 27: 833–840.
- 8. Bi Y, Ehirchiou D, Kilts TM, Inkson CA, Embree MC, et al. (2007) Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 13: 1219–1227.
- 9. Jozsa L, Kannus P (1997) Human Tendons: Anatomy, Physiology, and Pathology. Champaign, IL.
- 10. Kannus P (2000) Structure of the tendon connective tissue. Scand J Med Sci Sports 10: 312–320.
- 11. Woo SL, Debski RE, Zeminski J, Abramowitch SD, Saw SS, et al. (2000) Injury and repair of ligaments and tendons. Annu Rev Biomed Eng 2: 83–118.
- 12. Coussens LM, Tinkle CL, Hanahan D, Werb Z (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481–490.
- 13. Heissig B, Nishida C, Tashiro Y, Sato Y, Ishihara M, et al. (2010) Role of neutrophil-derived matrix metalloproteinase-9 in tissue regeneration. Histology and histopathology 25: 765–770.
- 14. Karousou E, Ronga M, Vigetti D, Passi A, Maffulli N (2008) Collagens, proteoglycans, MMP-2, MMP-9 and TIMPs in human achilles tendon rupture. Clinical orthopaedics and related research 466: 1577–1582.
- 15. Parkinson J, Samiric T, Ilic M, Cook J, Feller J, et al. (2010) Change in proteoglycan metabolism is a characteristic of human patellar tendinopathy. Arthritis Rheum 62: 3028–3035.
- 16. Voloshin I, Gelinas J, Maloney MD, O’Keefe RJ, Bigliani LU, et al. (2005) Proinflammatory cytokines and metalloproteases are expressed in the subacromial bursa in patients with rotator cuff disease. Arthroscopy 21: 1076.
- 17. Hsu JY, Bourguignon LY, Adams CM, Peyrollier K, Zhang H, et al. (2008) Matrix metalloproteinase-9 facilitates glial scar formation in the injured spinal cord. J Neurosci 28: 13467–13477.
- 18. Corbel M, Belleguic C, Boichot E, Lagente V (2002) Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol 18: 51–61.
- 19. Busch SA, Horn KP, Silver DJ, Silver J (2009) Overcoming macrophage-mediated axonal dieback following CNS injury. The Journal of neuroscience : the official journal of the Society for Neuroscience 29: 9967–9976.
- 20. Lim DH, Cho JY, Miller M, McElwain K, McElwain S, et al. (2006) Reduced peribronchial fibrosis in allergen-challenged MMP-9-deficient mice. American journal of physiology Lung cellular and molecular physiology 291: L265–271.
- 21. Mukherjee R, Colbath GP, Justus CD, Bruce JA, Allen CM, et al. (2010) Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury. The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 24: 3819–3828.
- 22. Rosenberg GA, Cunningham LA, Wallace J, Alexander S, Estrada EY, et al. (2001) Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures. Brain research 893: 104–112.
- 23. Scabilloni JF, Wang L, Antonini JM, Roberts JR, Castranova V, et al. (2005) Matrix metalloproteinase induction in fibrosis and fibrotic nodule formation due to silica inhalation. American journal of physiology Lung cellular and molecular physiology 288: L709–717.
- 24. Tan RJ, Fattman CL, Niehouse LM, Tobolewski JM, Hanford LE, et al. (2006) Matrix metalloproteinases promote inflammation and fibrosis in asbestos-induced lung injury in mice. American journal of respiratory cell and molecular biology 35: 289–297.
- 25. Wang L, Mercer RR, Rojanasakul Y, Qiu A, Lu Y, et al. (2010) Direct fibrogenic effects of dispersed single-walled carbon nanotubes on human lung fibroblasts. Journal of toxicology and environmental health Part A 73: 410–422.
- 26. Zhou J, Tang PC, Qin L, Gayed PM, Li W, et al. (2010) CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. The Journal of experimental medicine 207: 1951–1966.
- 27. Gieling RG, Wallace K, Han YP (2009) Interleukin-1 participates in the progression from liver injury to fibrosis. American journal of physiology Gastrointestinal and liver physiology 296: G1324–1331.
- 28. Natividad A, Cooke G, Holland MJ, Burton MJ, Joof HM, et al. (2006) A coding polymorphism in matrix metalloproteinase 9 reduces risk of scarring sequelae of ocular Chlamydia trachomatis infection. BMC medical genetics 7: 40.
- 29. Kajikawa Y, Morihara T, Watanabe N, Sakamoto H, Matsuda K, et al. (2007) GFP chimeric models exhibited a biphasic pattern of mesenchymal cell invasion in tendon healing. J Cell Physiol 210: 684–691.
- 30. Kollet O, Shivtiel S, Chen YQ, Suriawinata J, Thung SN, et al. (2003) HGF, SDF-1, and MMP-9 are involved in stress-induced human CD34+ stem cell recruitment to the liver. The Journal of clinical investigation 112: 160–169.
- 31. Wang L, Luo J, He S (2007) Induction of MMP-9 release from human dermal fibroblasts by thrombin: involvement of JAK/STAT3 signaling pathway in MMP-9 release. BMC cell biology 8: 14.
- 32. Warner RL, Bhagavathula N, Nerusu KC, Lateef H, Younkin E, et al. (2004) Matrix metalloproteinases in acute inflammation: induction of MMP-3 and MMP-9 in fibroblasts and epithelial cells following exposure to pro-inflammatory mediators in vitro. Experimental and molecular pathology 76: 189–195.
- 33. Ingraham CA, Park GC, Makarenkova HP, Crossin KL (2011) Matrix metalloproteinase (MMP)-9 induced by Wnt signaling increases the proliferation and migration of embryonic neural stem cells at low O2 levels. The Journal of biological chemistry.
- 34. Nee L, Tuite N, Ryan MP, McMorrow T (2007) TNF-alpha and IL-1 beta-mediated regulation of MMP-9 and TIMP-1 in human glomerular mesangial cells. Nephron Experimental nephrology 107: e73–86.
- 35. Turner NA, Aley PK, Hall KT, Warburton P, Galloway S, et al. (2007) Simvastatin inhibits TNFalpha-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Journal of molecular and cellular cardiology 43: 168–176.
- 36. Wu CY, Hsieh HL, Sun CC, Yang CM (2009) IL-1beta induces MMP-9 expression via a Ca2+-dependent CaMKII/JNK/c-JUN cascade in rat brain astrocytes. Glia 57: 1775–1789.
- 37. Xia L, Shen H, Lu J, Xiao W (2011) TRAF2 and cIAP2 involve in TWEAK-induced MMP-9 production in fibroblast-like synoviocytes. Rheumatology international.
- 38. Muroski ME, Roycik MD, Newcomer RG, Van den Steen PE, Opdenakker G, et al. (2008) Matrix metalloproteinase-9/gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis. Current pharmaceutical biotechnology 9: 34–46.
- 39. Katzel EB, Wolenski M, Loiselle AE, Basile P, Flick LM, et al. (2011) Impact of Smad3 loss of function on scarring and adhesion formation during tendon healing. Journal of orthopaedic research : official publication of the Orthopaedic Research Society 29: 684–693.
- 40. Aslan H, Kimelman-Bleich N, Pelled G, Gazit D (2008) Molecular targets for tendon neoformation. J Clin Invest 118: 439–444.
- 41. Hoffmann A, Pelled G, Turgeman G, Eberle P, Zilberman Y, et al. (2006) Neotendon formation induced by manipulation of the Smad8 signaling pathway in mesenchymal stem cells. J Clin Invest 116: 940–952.
- 42. Shahab-Osterloh S, Witte F, Hoffmann A, Winkel A, Laggies S, et al. (2010) Mesenchymal stem cell-dependent formation of heterotopic tendon-bone insertions (osteotendinous junctions). Stem Cells 28: 1590–1601.
- 43. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, et al. (1997) Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family. J Clin Invest 100: 321–330.
- 44. Beredjiklian PK, Favata M, Cartmell JS, Flanagan CL, Crombleholme TM, et al. (2003) Regenerative versus reparative healing in tendon: a study of biomechanical and histological properties in fetal sheep. Ann Biomed Eng 31: 1143–1152.
- 45. Strickland JW (1995) Flexor Tendon Injuries: I. Foundations of Treatment. J Am Acad Orthop Surg 3: 44–54.
- 46. Kulick MI, Smith S, Hadler K (1986) Oral ibuprofen: evaluation of its effect on peritendinous adhesions and the breaking strength of a tenorrhaphy. J Hand Surg Am 11: 110–120.
- 47. Virchenko O, Skoglund B, Aspenberg P (2004) Parecoxib impairs early tendon repair but improves later remodeling. Am J Sports Med 32: 1743–1747.
- 48. Hu J, Van den Steen PE, Sang QX, Opdenakker G (2007) Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nature reviews Drug discovery 6: 480–498.
- 49. Hasslund S, Jacobson JA, Dadali T, Basile P, Ulrich-Vinther M, et al. (2008) Adhesions in a murine flexor tendon graft model: autograft versus allograft reconstruction. J Orthop Res 26: 824–833.
- 50. Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, et al. (2009) In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. Blood 114: 4054–4063.